“While patients treated on regimens A and B were …% at 5 years, respectively), patients treated on regimen C were at a 16-fold increased risk of developing t-MDS/AML (cumulative incidence: 11% … 90 to 140 g/m2, cyclophosphamide from 9.6 to 17.6 g/m2, and doxorubicin ….”